Editas Medicine Files 8-K

TL;DR

EDAS filed an 8-K on Sept 2nd, covering Reg FD, other events, and financials.

AI Summary

Editas Medicine, Inc. filed an 8-K on September 2, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.

Why It Matters

This 8-K filing provides updates on Editas Medicine's corporate activities and financial reporting, which are crucial for investors to understand the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Editas Medicine, Inc. (company) — Registrant
• September 2, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Cambridge, Massachusetts (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto

Filing Documents

• edit-20250902.htm (8-K) — 36KB
• final_edit-401pressrelease.htm (EX-99) — 22KB
• imagea.jpg (GRAPHIC) — 8KB
• 0001650664-25-000134.txt ( ) — 203KB
• edit-20250902.xsd (EX-101.SCH) — 2KB
• edit-20250902_def.xml (EX-101.DEF) — 3KB
• edit-20250902_lab.xml (EX-101.LAB) — 23KB
• edit-20250902_pre.xml (EX-101.PRE) — 14KB
• edit-20250902_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 2, 2025, Editas Medicine, Inc. (the "Company") issued a press release titled "Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate," a copy of which is furnished as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. Nomination of Lead Development Candidate On September 2, 2025, the Company announced the nomination of its lead in vivo development candidate, EDIT-401, a therapy designed to reduce LDL cholesterol ("LDL-C") levels. EDIT-401 is an experimental in vivo gene editing medicine, based on Editas' differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. This targeted approach has demonstrated a favorable preclinical profile in both efficacy data and tolerability and supports the potential of EDIT-401 to deliver meaningful clinical outcomes for patients underserved by current lipid-lowering therapies. EDIT-401 is designed to be a one-time treatment that can provide lifelong benefit. In preclinical studies in non-human primates, EDIT-401 achieved approximately 90 percent mean reduction of LDL-C levels. This level of reduction was observed following a single dose of EDIT-401 (at all four dose levels of EDIT-401 evaluated, from 1.5 mg/kg to 4 mg/kg), as early as 48 hours after dosing and was sustained for the one-month study duration. In addition, in these preclinical studies, EDIT-401 increased the liver's production of the LDLR protein, a protein that removes LDL-C from the blood stream. Specifically, in these studies, the Company observed an at least six-fold mean increase in LDLR protein levels following treatment with EDIT-401. Additionally, there were no adverse effects observed. There were transient increases in liver enzymes that resolved within one week. Hematopoietic Stem Cells Program Update and Pipeline The Company intends to continue work on optimizing candidates for its Hematopoietic Stem Cell program and to continue exploring other cell types and tissues for development, but plans to focus its resources on the advancement of its lead EDIT-401 program to human proof-of-concept. Key Upcoming Planned Milestones Th

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate,'' believe,'' continue,'' could,'' estimate,'' expect,'' intend,'' may,'' plan,'' potential,'' predict,'' project,'' target,'' should,'' would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Current Report on Form 8-K include statements regarding the initiation, timing, progress and results of the Company's preclinical studies and its research and development programs, including the Company's expectation to achieve human proof-of-concept data for EDIT-401 by end of 2026 and identify and disclose an additional target cell type or tissue by the end of 2025; the potential of, and expectations for, EDIT-401; the timing or likelihood of regulatory filings and approvals, including submission of an IND or CTA for EDIT-401 by mid-2026; and the Company's expectations regarding its cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials; availability and timing of results from preclinical studies and clinical trials; expectations for regulatory approvals to conduct trials; that the outcome of preclinical testing may not be indicative of the results of clinical trials and early clinical trials may not be predictive of the outcomes of later clinical trials; that preclinical data of one comp

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on September 2, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: September 2, 2025 By: /s/ Amy Parison Amy Parison Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR